Get the Stockscreener App
3.41
0.59%
0.02
After Hours:
3.41
Prime Medicine Inc stock is traded at $3.41, with a volume of 2.69M.
It is up +0.59% in the last 24 hours and up +2.10% over the past month.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
See More
Previous Close:
$3.39
Open:
$3.45
24h Volume:
2.69M
Relative Volume:
1.11
Market Cap:
$615.90M
Revenue:
$4.63M
Net Income/Loss:
$-201.14M
P/E Ratio:
-2.4816
EPS:
-1.3741
Net Cash Flow:
$-167.10M
1W Performance:
-3.40%
1M Performance:
+2.10%
6M Performance:
-18.42%
1Y Performance:
+156.39%
1-Day Range:
$3.28
$3.485
1-Week Range:
$3.28
$3.685
52-Week Range:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.41 | 612.29M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Oppenheimer | Outperform |
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
PRME SEC FilingsPrime Medicine 10-K, 10-Q, 8-K Forms - Stock Titan
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen - MarketBeat
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Prime Medicine, Inc. ($PRME) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Prime Medicine, Inc. SEC Filing - Stock Titan
Prime Medicine (NASDAQ: PRME) details 2026 meeting, board elections and pay - Stock Titan
PRME (Prime Medicine Inc.) posts 55 percent year over year Q4 2025 revenue growth, shares rise modestly. - Xã Thanh Hà
Prime Medicine slides after pricing $125.4M stock offering - MSN
HC Wainwright & Co. Downgrades Prime Medicine (PRME) - MSN
Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer - Yahoo Finance
Bristol Myers Squibb (BMY) – Gene Editing Partner Prime Medicine (PRME) Announces Strategic CFO Hire, Bullish Analyst InitiationRisk Report - Cổng thông tin điện tử tỉnh Lào Cai
Prime Medicine (PRME) Financials 2026Income Statement and Balance Sheet - MarketBeat
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (PRME) awards CFO 800,000 stock options at $3.67 - Stock Titan
Prime Medicine (PRME) CFO Makhni Svetlana Ni submits initial Form 3 - Stock Titan
Prime Medicine names Svetlana Makhni as chief financial officer By Investing.com - Investing.com Australia
Prime Medicine appoints Svetlana Makhni as CFO By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Prime Medicine names Svetlana Makhni as chief financial officer - Investing.com
Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer - marketscreener.com
Prime Medicine Appoints Svetlana Makhni as New CFO - TipRanks
Prime Medicine appoints Svetlana Makhni as chief financial officer By Investing.com - Investing.com Australia
Prime Medicine appoints Svetlana Makhni as chief financial officer - Investing.com
Prime Medicine appoints Svetlana Makhni as CFO - Investing.com
CFO package at Prime Medicine (NASDAQ: PRME) details pay, options and severance - Stock Titan
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer - The Manila Times
Prime Medicine hires CFO as it prepares for two clinic entries - Stock Titan
Short Covering: Whats the fair value of Prime Medicine Inc stockTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.4%Here's What Happened - MarketBeat
Is Prime Medicine (PRME) Stock trading below intrinsic value | Price at $3.29, Down 6.41%Trending Picks - Cổng thông tin điện tử Tỉnh Sơn La
Prime Medicine slips after Q4 updates - MSN
PRME PE Ratio & Valuation, Is PRME Overvalued - Intellectia AI
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):